US2019183883A1PendingUtilityA1

Sustained Release Formulation Of Naltrexone

Assignee: NALPROPION PHARMACEUTICALS INCPriority: Jun 5, 2006Filed: Feb 25, 2019Published: Jun 20, 2019

Est. expiryJun 5, 2026(expired)· nominal 20-yr term from priority

Inventors:Anthony A. Mckinney Gary Tollefson Richard Soltero Thea Elise Dunzo

A61K 31/137A61K 31/485A61K 9/2054A61K 9/2009A61K 9/2027A61K 31/12A61K 9/0053A61K 9/2031A61K 9/2013A61K 9/20A61K 9/2018A61K 9/209

PatentIndex Score

Cited by

References

Claims

Abstract

A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment. The oral dosage form may be administered to treat a weight-loss condition.

Claims

exact text as granted — not AI-modified

1 - 42 . (canceled) 
     
     
         43 . An oral dosage form, comprising:
 a sustained-release formulation of naltrexone or a pharmaceutically acceptable salt thereof, and   bupropion or a pharmaceutically acceptable salt thereof.   
     
     
         44 . A method of treating overweight or obesity, the method comprising administering the oral dosage form of  claim 43 .

Join the waitlist — get patent alerts

Track US2019183883A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.